

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 January 2002 (17.01.2002)

PCT

(10) International Publication Number
WO 02/04419 A2

(51) International Patent Classification⁷: **C07D 211/00**

08902 (US). **PATEL, Mahendra, R.** [US/US]; 18 Timothy Lane, East Brunswick, NJ 08816 (US).

(21) International Application Number: PCT/US01/21623

(22) International Filing Date: 10 July 2001 (10.07.2001)

(74) Agents: **FURMAN, Diane, E.** et al.; Novartis Pharmaceuticals Corporation, Patent & Trademark Department, 564 Morris Avenue, Summit, NJ 07901-1027 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/614,295 12 July 2000 (12.07.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/614,295 (CIP)
Filed on 12 July 2000 (12.07.2000)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **GENEVA PHARMACEUTICALS, INC.** [US/US]; 2655 West Midway Boulevard, Broomfield, CO 80038 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **RAY, Anup, Kumar** [IN/US]; Apt. 3G, 285 St. Marks Place, Staten Island, NY 10301 (US). **PATEL, Hiren, Kumar, V.** [IN/US]; Apt. 3A, 15 Kearny Avenue, Edison, NJ 08817 (US). **MERALI, Shilpa, V.** [IN/US]; 97 Aspen Drive, North Brunswick, NJ

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: α,α -DIBROMO- α -CHLORO-ACETOPHENONES AS SYNTHONS

(57) Abstract: This disclosure relates to the use of α,α -dibromo- α -chloroacetophenone compounds as intermediates for the preparation of aromatic carbonyl compounds, especially aromatic amides. The compound 2,5-bis(2,2,2-trifluoroethoxy)- α,α -dibromo- α -chloro-acetophenone is especially useful as an intermediate for the preparation of flecainide, a known pharmaceutical.

WO 02/04419 A2

α,α -DIBROMO- α -CHLORO-ACETOPHENONES AS SYNTHONS

5

Summary

α,α -Dibromo- α -chloro acetophenone compounds are reacted with nucleophiles to yield aromatic carbonyl compounds. In an important aspect, 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide is prepared by reacting 2,5-bis(2,2,2-trifluoroethoxy)- α,α -dibromo- α -chloro acetophenone with 2-(2-aminomethyl)pyridine and reducing the piperidine ring.

Background

15 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide (III) is a known medicament useful for the treatment of arrhythmia and is described in U.S. Patent No. 3,900,481. It is commercially available as its acetate salt. Methods for its synthesis are described, for example, in U.S. Patent Nos. 4,642,384 and 4,617,396.

20 The synthetic method described in U.S. Patent No. 4,642,384 involves the preparation of 2,5-bis(2,2,2-trifluoroethoxy)- α,α -dichloroacetophenone as an intermediate by chlorinating the α -unsubstituted 2,5-bis(2,2,2-trifluoroethoxy)acetophenone with chlorine gas at a moderate temperature, such as 50-60°C. The α,α -dichloroacetophenone intermediate is further chlorinated in the presence of a buffering base, such as sodium acetate, at a slightly higher temperature, such as 80-100°C to yield the α,α,α -trichloroacetophenone. The α,α,α -trichloroacetophenone is reacted with 2-aminomethylpyridine to yield a benzamide, and the pyridine ring is reduced to yield 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide.


30 The inventive process is based on the discovery that the α,α -dibromo- α -chloroacetophenone is easily prepared in high yield and purity under mild conditions, and that it is a superior leaving group in nucleophilic substitution reactions.

Detailed Description

In one aspect this invention relates to a process for preparing the anti-arrhythmic agent, 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide (III), commonly known as flecainide, and pharmaceutically acceptable salts thereof, in particular the acetate salt.


The synthetic route comprises the reaction of 2,5-bis(2,2,2-trifluoroethoxy)- α,α -dibromo- α -chloro acetophenone (I) with 2-(aminomethyl)pyridine to form the corresponding benzamide (II). The pyridyl ring of the benzamide (II) is then reduced to the piperidinyll moiety yielding the desired compound, flecainide acetate (III). The reaction scheme with preferred reagents is set forth below:

Step 1:



Since the bulky dibromochloromethyl group is an excellent leaving group, (I) undergoes a facile amidization reaction with 2-aminomethylpyridine under mild conditions, such as at room temperature. It is preferred to carry out the reaction in an inert, non-polar solvent, such as toluene, hexane and the like, preferably a mixture of toluene and hexane.

Step 2:




The reduction of pyridine rings to piperidine rings is well known and can be effected many means, such as hydrogenation, or reduction with a metal hydride, a metal or dithionite. Hydrogenation is carried out by contacting a solution of the benzamide (II) with hydrogen in the presence of a hydrogenation catalyst, such as Pt/C, Pt, Pt/PtO₂, Pd/C, Rh/C, or Raney nickel. However, since it is unnecessary to protect any of the other functional groups in the molecule when the reduction is carried out by hydrogenation with a platinum-carbon catalyst, and since yields and purity are excellent, hydrogenation with a platinum-carbon catalyst is preferred.


Alternatively, for the preparation of flecainide, 2,5-bis(2,2,2-trifluoroethoxy)- α,α -dibromo- α -chloro acetophenone (I) can be reacted directly with 2-aminomethylpiperidine, avoiding the reduction step. However, the formation of impurities makes the two-step synthetic scheme described above preferable.

This invention further relates to the synthon 2,5-bis(2,2,2-trifluoroethoxy)- α,α -dibromo- α -chloro acetophenone (I). The bulky dibromochloromethyl group is an excellent leaving group for nucleophilic substitution reactions.

2,5-bis(2,2,2-trifluoroethoxy)- α,α -dibromo- α -chloro acetophenone (I) is preferably prepared from 2,5-bis(2,2,2-trifluoroethoxy)- α -chloro-acetophenone by reaction with bromine, preferably under neutral or acidic conditions, such as in glacial acetic acid in the presence of sodium acetate. Alternatively, other bromination methods, such as reaction with an N-bromoamide like N-bromosuccinimide, are also useful.



The 2,5-bis(2,2,2-trifluoroethoxy)-α-chloroacetophenone starting material is prepared by known methods. For example, a monochloro acetyl group is introduced to the ortho position of 1,4-bis(2,2,2-trifluoroethoxy)-benzene by a Friedel Crafts reaction using 2-chloroacetylchloride and a Lewis acid catalyst, such as tin chloride, ferric chloride or preferably, aluminum chloride, in the presence of a chlorinated hydrocarbon solvent, preferably methylene chloride.




The 1,4-bis(2,2,2-trifluoroethoxy)-benzene in turn is prepared by reacting 1,4-dibromobenzene with sodium 2,2,2-trifluoroethoxylate in the presence of cupric bromide as described in U.S. Patent Nos. 4,684,733 and 4,650,873, which are here incorporated by reference.

The present invention further relates to the use of an α,α-dibromo-α-chloro acetophenone as a reagent in nucleophilic substitution reactions whereby the bulky dibromochloromethyl group is a leaving group that is replaced by a nucleophile, such as an amine, an alcohol, a mercaptan, an amide or a carbanion-forming compound. Particularly interesting carbanion forming compounds are carbonyl compounds having an α-hydrogen atom, for example, ketones and esters having a methyl or methylene group adjacent to the carbonyl group, and Grignard reagents. Thus, the present invention includes a process for preparing an aromatic carbonyl compound, which comprises (a)

preparing an α,α -dibromo- α -chloro derivative of an acetophenone compound and (b) reacting the α,α -dibromo- α -chloro derivative of the acetophenone compound with an amine, an alcohol, a mercaptan, an amide or a carbanion-forming compound.

- 5 The instance where the aromatic carbonyl compound is a benzamide is an important process of the present invention. Thus, the present invention further relates to a process for preparing a benzamide which comprises reacting an α,α -dibromo- α -chloro acetophenone compound with a primary or secondary amine.

10



- The phenyl ring of the α,α -dibromo- α -chloro acetophenone compound is unsubstituted or substituted by R_1 and R_2 substituents which are independently, for example, hydrogen, C_1 - C_6 -alkyl, C_3 - C_7 -cycloalkyl, C_1 - C_6 -alkoxy, $-N(C_1$ - C_6 -alkyl) $_2$, $-S$ - C_1 - C_6 -alkyl, or phenyl; wherein the alkyl groups are unsubstituted or substituted by one or more halogen, hydroxy, $-S$ -alkyl, $-O$ -alkyl, carboxy, amido, or ester groups and when R_1 or R_2 is a phenyl substituent it is unsubstituted or substituted in the phenyl ring by halogen, C_1 - C_6 -alkyl, C_3 - C_7 -cycloalkyl, C_1 - C_6 -alkoxy, $-N(C_1$ - C_6 -alkyl) $_2$, or $-S$ - C_1 - C_6 -alkyl wherein the alkyl groups are unsubstituted or substituted by one or more halogen, hydroxy, $-S$ -alkyl, $-O$ -alkyl, carboxy, amido, or ester groups; or R_1 and R_2 together with the phenyl ring carbons to which they are attached form a 5-7 member aliphatic, aromatic, heterocyclic or heteroaromatic ring.

25

- One embodiment includes those compounds wherein the phenyl ring of the α,α -dibromo- α -chloro acetophenone compound is unsubstituted or substituted by R_1 and R_2 substituents which are independently hydrogen, C_1 - C_6 -alkyl, C_3 - C_7 -cycloalkyl, C_1 - C_6 -alkoxy, $-N(C_1$ - C_6 -alkyl) $_2$, or $-S$ - C_1 - C_6 -alkyl; wherein the alkyl groups are unsubstituted or substituted by one or more halogen, hydroxy, $-S$ -alkyl, $-O$ -alkyl, carboxy, amido, or ester groups. An alternate embodiment include those compounds wherein R_1 and R_2 are

30

independently hydrogen, C₁-C₄-alkyl, C₃-C₇-cycloalkyl, or C₁-C₄-alkoxy wherein the alkyl groups are unsubstituted or substituted by one or more halogen, hydroxy, or -O-alkyl substituents. Further alternate embodiments include those compounds wherein at least one of R₁ and R₂ is substituted or unsubstituted C₁-C₄-alkyl; substituted or unsubstituted C₃-C₇-cycloalkyl; substituted or unsubstituted C₁-C₄-alkoxy; substituted or unsubstituted -N(C₁-C₄-alkyl)₂; or substituted or unsubstituted -S-C₁-C₄-alkyl.

Preferably, R₁ is in the 4-position when R₂ is hydrogen, or R₁ is in the 2-position and R₂ is in the 5-position when R₂ is other than hydrogen.

10


The nitrogen substituents, R₃ and R₄, are independently, for example, hydrogen or unsubstituted C₁-C₆-alkyl or C₁-C₆-alkyl which is substituted by one or more of, for example, -OH, halogen, alkoxy, or an aliphatic, aromatic, heterocyclic or heteroaromatic ring; or R₃ and R₄ together with the nitrogen atom form a heterocyclic ring such as a piperidine, piperazine, pyrrole, or morpholine ring.

15

Examples of suitable α,α -dibromo- α -chloro acetophenone compounds include 2-hydroxy-5-chloro- α,α -dibromo- α -chloro acetophenone which is reacted with 2-chloro-4-nitro-aniline to yield the therapeutic agent niclosamide.

20

The present invention further relates to α,α -dibromo- α -chlorophenone compounds of the formula



(II)

25

wherein R₁ and R₂, and the embodiments thereof, are described above. The compounds are useful as intermediates for the preparation of aromatic carbonyl compounds.

The following examples are intended to illustrate, but not limit, the inventive process.

30

Example 11,4-BIS(2,2,2-TRIFLUOROETHOXY)-BENZENE

5 30.0 g (0.75 mole, 60% dispersion in oil) of anhydrous sodium hydride is added to a three-necked round bottom flask (500 mL) fitted with a condenser a with CaCl₂ guard tube, a nitrogen inlet and a dropping funnel. 160 ml of dry dimethylformamide is added to make slurry. The slurry is cooled in ice water and 2,2,2-trifluoroethanol (75 mL, 1.03 mole) is added drop wise resulting in an exothermic reaction. The temperature inside the flask is
10 maintained below 30°C. During the addition of 2,2,2-trifluoroethanol, the mixture first becomes yellow in color and then becomes a brown clear solution. After the addition of the 2,2,2-trifluoroethanol is complete, the reaction mixture is stirred at room temperature for 30 minutes under a nitrogen blanket. 30.0 g (0.13 mole) of 1,4-dibromobenzene and 3.75 g of cupric bromide are then added. The resulting mixture is heated to 100°C with
15 vigorous stirring for 2.5 hours. The reaction mixture is then cooled to room temperature and quenched with ice-water (1500 mL). The aqueous phase is acidified with about 50-55 ml of concentrated HCl. The resulting solid is filtered with vacuum and washed with copious amount of water. The violet-colored solid is dried overnight under vacuum in a desiccator over P₂O₅. The dried solid is dissolved in diethyl ether and filtered. The filtrate
20 is evaporated resulting in an off-white solid (34.5 g, yield 99%), which is crystallized in n-hexane to yield needle-shaped crystals of 1,4-bis(2,2,2-trifluoroethoxy)-benzene.
m.p. 74-77°C
MS: M⁺ 274 (EI-MS)
¹H NMR (CDCl₃): δ 4.32 (4H,q,2,5-O-CH₂-CF₃), δ 6.91 (4H,s, 1,3,4,6-H)

25

Example 22,5-BIS(2,2,2-TRIFLUOROETHOXY)-α-CHLORO ACETOPHENONE

30 A two-necked round bottom flask (250 mL) is fitted with a nitrogen inlet and a dropping funnel and 6.0 g (0.045 mole) of anhydrous aluminum chloride and 50.0 mL of dry methylchloride are added. A solution of 10.0 g (0.0365mole) of 1,4-bis(2,2,2-trifluoroethoxy)benzene dissolved in dichloromethane (10 mL) is added drop wise at room temperature with stirring followed by 4.0 mL (0.05 mole) of 2-chloroacetylchloride . The
35 color of the solution slowly changes to red-brown. The mixture is stirred at room temperature for 2.5 hours. The red-brown colored solution is poured into a mixture of ice

water (200 mL) and 15.0 mL concentrated HCl and stirred for 20 minutes. The pink dichloromethane phase is separated, and the aqueous phase is extracted with dichloromethane (50 mL \times 2). The combined dichloromethane phases are washed with:
i) H₂O (100 mL \times 2) ii) 5% NaOH (50 mL \times 2) and iii) H₂O (100 mL \times 2) and the resulting
5 yellow solution is dried over anhydrous sodium sulfate and then evaporated under reduced pressure resulting in a yellow solid (11.5 g, yield 90%). Crystallization from n-hexane results in a shining white crystals of 2,5-bis(2,2,2-trifluoroethoxy)- α -chloroacetophenone.

m.p. 76-78°C

10 MS: M⁺ 350 (EI-MS)

¹H NMR: δ 4.38 (2H,q,5-O-CH₂-CF₃), δ 4.48 (2H,q,-2-O-CH₂-CF₃), δ 4.75 (2H,s, 1'-C=O-CH₂-Cl), δ 6.9 (1H,o-d, J=9.1 Hz, 3-H), δ 7.2 (1H,o-m-dd, J_{o-m} = 8.6, 3.1 Hz, 4-H), δ 7.48 (1H, m-d, J_m = 3.1 Hz, 6-H)

15

Example 3

2,5-BIS(2,2,2-TRIFLUOROETHOXY)- α,α -DIBROMO- α -CHLORO ACETOPHENONE

2.0 g (0.0057 mole) of 2,5-bis(2,2,2-trifluoroethoxy)- α -chloroacetophenone, 2.8 g
20 (0.034 mole) of anhydrous sodium acetate and 12.0 mL of glacial acetic acid are added to a 100 ml two necked round bottom flask. The mixture is stirred and heated to 70°C in an oil bath. 0.63 mL (0.0113 mole) of bromine are added drop wise maintaining the temperature at about 65-70°C, and the mixture is allowed to react for about one hour. The mixture is monitored by TLC (solvent system=ethyl acetate: hexane 4:1) until no 2,5-bis(2,2,2-trifluoroethoxy)- α -chloroacetophenone remains. When the reaction is
25 completed, the solution is poured into 100 mL of ice water, and the aqueous fraction is extracted with dichloromethane (15 mL \times 3). The organic phase is then washed with: i) 5% NaHCO₃ (10 mL \times 2) and ii) deionized H₂O (15 mL \times 2) and then dried over anhydrous Na₂SO₄. Evaporation of the dichloromethane under reduced pressure results in a thick
30 syrupy liquid, which solidifies when cooled. Washing with n-hexane yields 2,5-bis(2,2,2-trifluoroethoxy)- α,α -dibromo- α -chloro acetophenone as a brown solid (2.8 g, yield 98%).

m.p. 42-43°C

MS: M⁺ 506 (EI-MS), (M + H)⁺ 507 (CI-MS)

¹H NMR (CDCl₃): δ 4.5 (4H,two quartet merge,2,5-O-CH₂-CF₃), δ 6.97 (1H,o-d, J=9.2 Hz, 3-H), δ 7.09 (1H,o, m-dd, J= 9.2, 3.1 Hz, 4-H), δ 7.35 (1H, m-d, J= 3.1 Hz, 6-H)

35

Example 42,5-BIS(2,2,2-TRIFLUOROETHOXY)-N-(2-PYRIDYLMETHYL)-BENZAMIDE

12.0 g (23.7 mmoles) of 2,5-bis(2,2,2-trifluoroethoxy)- α , α -dibromo- α -chloro acetophenone is added to a 250 ml round bottom flask and dissolved in 14.5 mL of toluene and stirred at room temperature. 2.82 g (26.07 mmoles) of 2-(aminomethyl)-pyridine are shaken with a solvent mixture, hexane:toluene (5:1, 50.0 mL), and added to the round bottom flask over a period of about 20 minutes. When the addition is about half complete, a precipitate appears and makes stirring difficult. After the addition is completed, another 50.0 mL of hexane:toluene (5:1) mixture is added, and the mixture is stirred vigorously for another 3 hours. The reaction mixture is filtered yielding a light yellow solid, which is washed with n-hexane yielding 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-pyridylmethyl)-benzamide as an off-white solid (9.02 g, yield 93.4%).

m.p. 100-103°C

MS: M^+ 408 (EI-MS), $(M + H)^+$ 409 (CI-MS)

^1H NMR (CDCl_3): δ 4.4 (2H, q, 2-O-CH₂-CF₃), δ 4.5 (2H, q, 5-O-CH₂-CF₃), δ 4.8 (2H, d, 7'-H), δ 6.95 (1H, o-d, J = 9.1 Hz, 3-H), δ 7.1 (1H, dd, J = 3.0, 8.9 Hz, 4-H), δ 7.22 (1H, dd, J = 5.4, 7.2 Hz, 4'-H), δ 7.32 (1H, d, J = 7.9 Hz, 5'-H), δ 7.7 (1H, dd, J = 1.8, 7.7 Hz, 3'-H), δ 7.8 (1H, d, J = 3.4 Hz, 6-H), δ 8.56 (1H, d, J = 4.4 Hz, 2'-H), δ 8.6 (1H, br.s., 8'-H)

Example 52,5-BIS(2,2,2-TRIFLUOROETHOXY)-N-(2-PIPERIDYLMETHYL)-BENZAMIDE ACETATE

5.0 g (0.01225 mole) of 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-pyridylmethyl)-benzamide is dissolved in 30 mL glacial acetic acid in a pressure vessel (Parr Instrument Company). 0.515 g Pt-C (5% wt./wt.) is added to the vessel. The vessel is flushed with nitrogen and then with hydrogen. The solution is stirred for 23 hours with under hydrogen at a pressure of 30 lbs. The solution is then filtered on celite and washed with isopropyl alcohol. The filtrate is evaporated under reduced pressure. The resulting syrupy liquid is shaken vigorously with n-hexane to yield a yellowish white precipitate, which is washed with ether yielding an off-white solid. The solid 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide acetate is dried in the vacuum desiccator over P_2O_5 (4.5g, 89% yield) and then crystallized from isopropyl alcohol and isopropyl ether.

m.p. 149-151°C

MS: (CI-MS), $(M + H)^+$ 415


^1H NMR (CD_3OD): δ 1.45 – 2.1 (6H,m, 3',4',5'-H), δ 2.9 (1H,m, 6'-H), δ 3.2 – 3.45 (2H,br.d, m, 2'-H), δ 3.6 (2H,m, 7'-H), δ 4.54 (2H,q, 2-O- $\text{CH}_2\text{-CF}_3$), δ 4.7 (2H,q, 5-O- $\text{CH}_2\text{-CF}_3$), δ 7.2 (2H, s, 3-H, 4-H), δ 7.48 (1H, s, 6-H)

5

Examples 6-14





The α,α -dibromo- α -chloroacetophenone compounds set forth below are prepared in accordance the procedure set forth in Example 3 starting with the appropriately substituted α -chloroacetophenone:

10






(II)




Table 1

#	R ₁	R ₂
6	(2) -OCH ₃	(5) -OCH ₃
7	(2) -O- 	(5) -O- 
8	(2) -O-CH ₂ - 	(5) -O-CH ₂ - 
9	(2) -OCH ₃	(5) -OCH ₂ CH ₃
10	(4) -Cl	H
11	(4) -Br	H
12	(4) -CH ₃	H
13	H	H
14	(4) -OCH ₃	H

Example 15-20

The compounds in Table 2 are prepared by reacting the α,α -dibromo- α -chloroacetophenone compounds prepared above with the nucleophiles identified in Table 2 by a procedure analogous to that described in Example 4:

Table 2			
#	acetophenone	nucleophile	product
15	Example 3	$\text{HN}(\text{CH}_3)_2$	
16	Example 6	piperidine	
17	Example 6	N-methylpiperazine	

#	acetophenone	nucleophile	product
18	Example 6	2-aminomethyl-N-methylpiperidine	
19	Example 3	morpholine	
20	Example 3	2-aminomethyl-N-methylpiperidine	

Example 21

5 The compound prepared according to Example 20 is converted to flecainide by (1) reaction with ethylchloroformate to form the N-carboethoxypiperidinyl derivative, for example, by a procedure analogous to that described in U.S. Patent No. 4,282,233, followed by (2) decarbalkoxylation by known methods, for example, by a procedure



10

Examples 22 and 23

0.322 g (0.016 mole) of sodium metal is placed in a 250 ml three necked round bottom flask fitted with a condenser and a dropping funnel. 50 ml of dry ethanol are

15 added with cooling. After the addition is complete, the mixture is warmed to complete the formation of sodium ethoxide. The sodium ethoxide solution is added to 1.32 grams (0.015 mole) of dry ethyl acetate in Example 22 (or 1.62 g (0.015 mole) of benzyl alcohol in Example 23) and brought to room temperature. The mixture is then heated to 50-55°C

- for about one hour. The mixture is then cooled in an ice bath, and 0.016 mole of the α,α -dibromo- α -chloro acetophenone compound dissolved in toluene is added slowly. After the addition is complete, the mixture is brought to room temperature and stirred for 2 hours. The solvent is evaporated under vacuum and the residue dissolved in water, acidified and extracted with methylene chloride. The combined methylene chloride fractions are washed with saturated brine and dried over sodium sulfate. Finally, the solvent is removed to yield the product.
- 5

#	acetophenone	nucleophile	product
22	Example 6	ethylacetate	
23	Example 3	benzyl alcohol	

We claim:

1. A process for the preparation of 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide or a salt thereof, which comprises:
 - 5 (a) reacting 2,5-bis(2,2,2-trifluoroethoxy)- α,α -dibromo- α -chloro acetophenone with 2-(aminomethyl)pyridine to form 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-pyridylmethyl)-benzamide, and
 - (b) reducing the 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-pyridylmethyl)-benzamide.
- 10 2. A process of claim 1 wherein step (b) is carried out by exposing the 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-pyridylmethyl)-benzamide to hydrogen in the presence of a hydrogenation catalyst.
3. A process of claim 2 wherein the catalyst is platinum-carbon.
- 15 4. A process of claim 1 wherein the 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide is isolated as its acetate salt.
5. 2,5-bis(2,2,2-trifluoroethoxy)- α,α -dibromo- α -chloro-acetophenone.
- 20 6. A process for the preparation of 2,5-bis(2,2,2-trifluoroethoxy)- α,α -dibromo- α -chloro acetophenone which comprises reacting 2,5-bis(2,2,2-trifluoroethoxy)- α -chloro acetophenone with bromine.
- 25 7. A process of claim 6 wherein the 2,5-bis(2,2,2-trifluoroethoxy)- α -chloro acetophenone is prepared by reacting 1,4-di(2,2,2-trifluoroethoxy)benzene with 2-chloroacetylchloride in the presence of a Friedel Crafts catalyst.
8. A process of claim 7 wherein the Friedel Crafts catalyst is aluminum chloride.
- 30 9. A process for the preparation of 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-pyridylmethyl)-benzamide which comprises reacting 2,5-bis(2,2,2-trifluoroethoxy)- α,α -dibromo- α -chloro acetophenone with 2-(aminomethyl)pyridine.
- 35 10. A process for preparing an aromatic carbonyl compound, which comprises (a) converting an α -chloro derivative of an acetophenone compound to an α,α -dibromo- α -


chloro acetophenone compound and (b) reacting the α,α -dibromo- α -chloro acetophenone compound with an amine, an alcohol, a mercaptan, an amide or a carbanion-forming compound.

11. A process of claim 10 for preparing a benzamide which comprises reacting the α,α -dibromo- α -chloro acetophenone compound with a primary or secondary amine.

12. A process of claim 10 wherein the acetophenone compound is 2,5-bis(2,2,2-trifluoroethoxy)- α,α -dibromo- α -chloro acetophenone and the amine is with 2-

(aminomethyl)piperidine or 2-(aminomethyl)-N-methylpiperidine.

13. A compound of the formula



(II)

wherein R₁ and R₂ are independently hydrogen, C₁-C₆-alkyl, C₃-C₇-cycloalkyl, C₁-C₆-alkoxy, -N(C₁-C₆-alkyl)₂, -S-C₁-C₆-alkyl, or phenyl, wherein the alkyl groups are unsubstituted or substituted by one or more halogen, hydroxy, -S-alkyl, -O-alkyl, carboxy, amido, or ester groups and when the R₁ or R₂ substituent is phenyl it is unsubstituted or substituted in the phenyl ring by halogen, C₁-C₆-alkyl, C₃-C₇-cycloalkyl, C₁-C₆-alkoxy, -N(C₁-C₆-alkyl)₂, -S-C₁-C₆-alkyl, the alkyl groups of which are unsubstituted or substituted by one or more halogen, hydroxy, -S-alkyl, -O-alkyl, carboxy, amido, or ester groups; or R₁ and R₂ together with the phenyl ring carbons to which they are attached form a 5-7 member aliphatic, aromatic, heterocyclic or heteroaromatic ring.

14. A compound of claim 13 wherein R₁ and R₂ are independently hydrogen, C₁-C₄-alkyl, C₃-C₇-cycloalkyl, C₁-C₄-alkoxy, -N(C₁-C₄-alkyl)₂, or -S-C₁-C₄-alkyl; wherein the alkyl groups are unsubstituted or substituted by one or more halogen, hydroxy, -S-alkyl, -O-alkyl, carboxy, amido, or ester groups.

15. A compound of claim 13 wherein R₁ and R₂ are independently hydrogen, C₁-C₄-alkyl, C₃-C₇-cycloalkyl, or C₁-C₄-alkoxy wherein the alkyl groups are unsubstituted or substituted by one or more halogen, hydroxy, or -O-alkyl substituents.

16. A compound of claim 14 wherein at least one of R_1 and R_2 is substituted or unsubstituted C_1 - C_4 -alkyl; substituted or unsubstituted C_3 - C_7 -cycloalkyl; substituted or unsubstituted C_1 - C_4 -alkoxy; or substituted or unsubstituted -S- C_1 - C_4 -alkyl.

5

17. A compound of claim 14 wherein at least one of R_1 and R_2 is substituted or unsubstituted C_1 - C_4 -alkoxy.

10

18. A compound of claim 14 wherein R_1 is in the 4-position when R_2 is hydrogen, or R_1 is in the 2-position and R_2 is in the 5-position when R_2 is other than hydrogen.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 January 2002 (17.01.2002)

PCT

(10) International Publication Number
WO 02/04419 A3

(51) International Patent Classification⁷: C07D 211/56,
213/74

08902 (US). PATEL, Mahendra, R. [US/US]; 18 Timothy
Lane, East Brunswick, NJ 08816 (US).

(21) International Application Number: PCT/US01/21623

(74) Agents: FURMAN, Diane, E. et al.; Novartis Pharmaceu-
ticals Corporation, Patent & Trademark Department, 564
Morris Avenue, Summit, NJ 07901-1027 (US).

(22) International Filing Date: 10 July 2001 (10.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/614,295 12 July 2000 (12.07.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 09/614,295 (CIP)
Filed on 12 July 2000 (12.07.2000)

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): GENEVA
PHARMACEUTICALS, INC. [US/US]; 2655 West Mid-
way Boulevard, Broomfield, CO 80038 (US).

Published:

— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): RAY, Anup, Kumar
[IN/US]; Apt. 3G, 285 St. Marks Place, Staten Island,
NY 10301 (US). PATEL, Hiren, Kumar, V. [IN/US]; Apt.
3A, 15 Kearny Avenue, Edison, NJ 08817 (US). MERAI,
Shilpa, V. [IN/US]; 97 Aspen Drive, North Brunswick, NJ

(88) Date of publication of the international search report:
23 May 2002

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: α,α -DIBROMO- α -CHLORO-ACETOPHENONES AS SYNTHONS

(57) Abstract: This disclosure relates to the use of α,α -dibromo- α -chloroacetophenone compounds as intermediates for the prepa-
ration of aromatic carbonyl compounds, especially aromatic amides. The compound 2,5-bis(2,2,2-trifluoroethoxy)- α,α -dibromo- α -
chloro-acetophenone is especially useful as an intermediate for the preparation of flecainide, a known pharmaceutical.

WO 02/04419 A3

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D211/56 C07D213/74

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 642 384 A (LEIR CHARLES M) 10 February 1987 (1987-02-10) cited in the application	1-5, 9-18
Y	column 1, line 18 - line 20 example 8	6-8
A	----- DATABASE HCA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; Database accession no. 90:121213 XP002186210	5, 13-18
Y	abstract & PL 85 387 A (INSTYTUT PRZEMYSŁU ORGANICZNEGO) 30 April 1976 (1976-04-30) -----	6-8



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

*** Special categories of cited documents:*****A*** document defining the general state of the art which is not considered to be of particular relevance***E*** earlier document but published on or after the international filing date***L*** document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)***O*** document referring to an oral disclosure, use, exhibition or other means***P*** document published prior to the international filing date but later than the priority date claimed***T*** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention***X*** document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone***Y*** document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.***&*** document member of the same patent family

Date of the actual completion of the international search

20 December 2001

Date of mailing of the international search report

24/01/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hoepfner, W

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC1/US 01/21623

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4642384	A	10-02-1987	BE 882318 A1 19-09-1980
			CA 1137486 A1 14-12-1982
			CH 643829 A5 29-06-1984
			DE 3010195 A1 02-10-1980
			DK 79891 A 30-04-1991
			DK 112180 A 20-09-1980
			DK 122290 A ,B, 17-05-1990
			ES 489629 D0 01-04-1981
			ES 8104227 A1 01-07-1981
			FR 2454438 A1 14-11-1980
			FR 2468569 A1 08-05-1981
			FR 2468570 A1 08-05-1981
			FR 2468571 A1 08-05-1981
			FR 2468576 A1 08-05-1981
			FR 2468590 A1 08-05-1981
			FR 2468591 A1 08-05-1981
			GB 2045760 A ,B 05-11-1980
			GB 2097000 A ,B 27-10-1982
			IE 49559 B1 30-10-1985
			IE 49558 B1 30-10-1985
			IL 59623 A 31-07-1983
			IT 1195262 B 12-10-1988
			JP 1509615 C 26-07-1989
			JP 55143967 A 10-11-1980
			JP 63057429 B 11-11-1988
			JP 1104045 A 21-04-1989
			JP 1626935 C 28-11-1991
			JP 2051906 B 08-11-1990
			JP 1104043 A 21-04-1989
			JP 1626936 C 28-11-1991
			JP 2051907 B 08-11-1990
			JP 1104044 A 21-04-1989
			JP 1626937 C 28-11-1991
			JP 2051908 B 08-11-1990
			JP 1125339 A 17-05-1989
			JP 1706039 C 27-10-1992
			JP 3072212 B 18-11-1991
			JP 1049695 B 25-10-1989
			JP 1125341 A 17-05-1989
			JP 1564527 C 12-06-1990
			JP 1125342 A 17-05-1989
			JP 1578955 C 13-09-1990
			JP 2002869 B 19-01-1990
			JP 1125343 A 17-05-1989
			JP 1578956 C 13-09-1990
			JP 2002870 B 19-01-1990
			JP 1125344 A 17-05-1989
			JP 1676377 C 26-06-1992
			JP 3039498 B 14-06-1991
			NL 8001551 A ,B, 23-09-1980
PL 85387	A	NONE	